Search This Blog

Monday, October 5, 2026

Vaxcyte's VAX-31 meets all primary endpoints in pivotal Phase 3 trial vs Prevnar 20 and Capvaxive

 


  • Topline data show immunogenicity, safety and immunobridging endpoints achieved, supporting planned BLA filing in first half of 2028.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)